1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea → 1-{3-tert-Butyl-1'-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1'H-[1,4']bipyrazolyl-5-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea
反応式
ClC(Cl)(Cl)CO[C:5](=[O:30])[NH:6][C:7]1[N:11]([C:12]2[CH:13]=[N:14][N:15]([CH2:17][CH2:18][O:19][CH:20]3[CH2:25][CH2:24][CH2:23][CH2:22][O:21]3)[CH:16]=2)[N:10]=[C:9]([C:26]([CH3:29])([CH3:28])[CH3:27])[CH:8]=1.C(C1C=C(NC([NH:53][C@@H:54]2[C:63]3[C:58](=[CH:59][CH:60]=[CH:61][CH:62]=3)[C@H:57]([O:64][C:65]3[CH:66]=[CH:67][C:68]4[N:69]([C:71]([N:74]5[CH2:79][CH2:78][CH2:77][CH2:76][CH2:75]5)=[N:72][N:73]=4)[CH:70]=3)[CH2:56][CH2:55]2)=O)N(C2C=CC(CO)=CC=2)N=1)(C)(C)C>>[C:26]([C:9]1[CH:8]=[C:7]([NH:6][C:5]([NH:53][C@@H:54]2[C:63]3[C:58](=[CH:59][CH:60]=[CH:61][CH:62]=3)[C@H:57]([O:64][C:65]3[CH:66]=[CH:67][C:68]4[N:69]([C:71]([N:74]5[CH2:75][CH2:76][CH2:77][CH2:78][CH2:79]5)=[N:72][N:73]=4)[CH:70]=3)[CH2:56][CH2:55]2)=[O:30])[N:11]([C:12]2[CH:13]=[N:14][N:15]([CH2:17][CH2:18][O:19][CH:20]3[CH2:25][CH2:24][CH2:23][CH2:22][O:21]3)[CH:16]=2)[N:10]=1)([CH3:27])([CH3:29])[CH3:28]参加物
3
反応物 2
HCID 716036691-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea
HCID 86687175{3-tert-Butyl-1'-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1'H-[1,4']bipyrazolyl-5-yl}-carbamic acid 2,2,2-trichloro-ethyl ester生成物 1
実験手順
The title compound was prepared starting from Intermediate 3c and Intermediate 108b using analogous procedures to those described in Intermediate 106a. LCMS (Method 4): Rt 3.27 min, m/z 723.5 [MH+].
出典と根拠
- ORDレコード
- ord-b54d15db35cb4a528ac36e83e42b331d
- 出典データセット
- uspto-grants-2016_04
- 特許番号
- US09315503B2
反応ノート
読み込み中…